Our present findings provide sufficient evidence to justify further studies focusing on the possibility of monitoring specific soluble forms of ADAM10 and to evaluate the progress and feasibility of developing molecular tools for this potential new CSF biomarker for AD. This evidence concerns the gene ADAM10 and Alzheimer disease.